Fosun Pharma (600196.SH) subsidiary signs licensing agreement with NuCotex, gaining rights to develop AR1001 drug in China, among others.

Zhtng Cijng APP News, Fosun Pharma (600196.SH) announced that on July 28, 2025, the company's controlling subsidiary Fosun Pharmaceutical Industry signed a License Agreement with Nuco. According to the agreement, Fosun Pharmaceutical Industry will be granted by Nuco the rights to develop, register, produce, and commercialize drugs with the AR1001 molecule as its active ingredient in the agreed license area (i.e. mainland China, Hong Kong, Macao) and field (i.e. for the diagnosis, prevention, and treatment of Alzheimer's disease and other neurological disorders). Under the agreement, Fosun Pharmaceutical Industry will pay Nuco up to 150 million RMB for this license (including the initial payment and regulatory milestone payments).